

1058 U.S. PTO

03-01-01

Box SEQ

A

UTILITY PATENT APPLICATION TRANSMITTAL		Attorney Docket No. C100-7017HCL/MAT
First Named Inventor or Application Identifier		
BRATZLER, Robert L.		
Express Mail Label No.		EL711263038US
Date of Deposit		March 5, 2001

JG29 U.S. PRO

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents		ADDRESS TO: Box Patent Application Commissioner for Patents Washington, DC 20231
<p>1. <input type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <ul style="list-style-type: none"> <input type="checkbox"/> Statement filed in prior application, status still proper and desired. <p>3. X Specification -Total pages - 73</p> <p style="margin-left: 20px;">66 - pages description</p> <p style="margin-left: 20px;">1 - pages abstract</p> <p style="margin-left: 20px;">6- pages claims 36- Total claims</p> <p>4. <input type="checkbox"/> Drawing(s) (35 USC 113) - Total sheets</p> <ul style="list-style-type: none"> <input type="checkbox"/> Informal <input type="checkbox"/> Formal - Total drawings <p>5. <input type="checkbox"/> Oath or Declaration - Total pages</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) [Note Box 6 below]</p> <p>i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Incorporation by Reference (usable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 18.</p> <p>7. <input type="checkbox"/> Application Data Sheet, See 37 CFR 1.76</p>		<p>8. <input type="checkbox"/> CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix)</p> <p>9. X Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <ul style="list-style-type: none"> a. X Computer Readable Form (CRF) b. X Specification Sequence Listing on: <ul style="list-style-type: none"> i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. X paper (identical to computer copy) c. X Statement verifying identity of above copies
ACCOMPANYING APPLICATION PARTS		
<p>10. <input type="checkbox"/> Assignment Papers/cover sheet & documents(s)</p> <p>11. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee)</p> <ul style="list-style-type: none"> <input type="checkbox"/> Power of Attorney <p>12. <input type="checkbox"/> English Translation of Document (if applicable)</p> <p>13. <input type="checkbox"/> Information Disclosure Statement/PTO-1449</p> <ul style="list-style-type: none"> <input type="checkbox"/> Copies of IDS Citations <p>14. <input type="checkbox"/> Preliminary Amendment</p> <p>15. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>16. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p> <p>17. X This application claims priority under Title 35 §119(e), of United States Provisional Application No. 60/187,214, filed March 3, 2000, and entitled IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT OF CANCER, the entire contents of which are incorporated herein by reference.</p>		

18. If a CONTINUING APPLICATION, check appropriate box and supply requisite information below and in the body of the application, or in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____, filed on _____, entitled _____ and now _____.

Prior application information: Examiner _____ Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER	 23628 PATENT TRADEMARK OFFICE
-----------------	--

20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	Helen C. Lockhart, Reg. No. 39248
SIGNATURE	
DATE	March 5, 2001